Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Zacks01-24

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2506893707?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-24 23:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2506893707","market":"us","top_or_hot":-1,"title":"Is it a Good Idea to Invest in Beam Therapeutics Stock Now?","media":"Zacks","content":"<div>\n<p>Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/good-idea-invest-beam-therapeutics-154000464.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is it a Good Idea to Invest in Beam Therapeutics Stock Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs it a Good Idea to Invest in Beam Therapeutics Stock Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-24 23:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/good-idea-invest-beam-therapeutics-154000464.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/good-idea-invest-beam-therapeutics-154000464.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/good-idea-invest-beam-therapeutics-154000464.html","article_id":"2506893707","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506893707","pubTimestamp":1737733200,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease , an inherited blood disorder.BEAM’s pipeline of gene editing therapies is based on its proprietary base editing technology.The company believes that its innovative next-generation technology called base-editing technology can provide a superior way to modify genes and could open up entirely new applications in gene editing, targeting a wide range of severe diseases. It can also make more precise single-base changes at specific locations in genes, resulting in predictable edits in all cells, without needing to damage or make double-stranded breaks in the DNA.Beam Therapeutics currently has a Zacks Rank #2 . In the past 60 days, estimates for BEAM’s 2025 loss per share have narrowed from $4.62 to $4.32.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.58 for 20","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4196":"保健护理服务","SCD":"LMP Capital & Income Fund","LENZ":"Therapeutics","HRMY":"Harmony Biosciences Holdings, Inc.","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BEAM":"Beam Therapeutics, Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4588":"碎股","CSTL":"Castle Biosciences, Inc.","BK4007":"制药","VYGR":"Voyager Therapeutics Inc"},"translate_title":"现在投资Beam Therapeutics股票是个好主意吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":1,"HRMY":1,"LENZ":1,"SCD":1,"VYGR":1,"BEAM":0.9},"content_text":"Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.\nBEAM’s pipeline of gene editing therapies is based on its proprietary base editing technology.\nThe company believes that its innovative next-generation technology called base-editing technology can provide a superior way to modify genes and could open up entirely new applications in gene editing, targeting a wide range of severe diseases. It can also make more precise single-base changes at specific locations in genes, resulting in predictable edits in all cells, without needing to damage or make double-stranded breaks in the DNA.\nGood Rank & Rising Estimates for BEAM\nBeam Therapeutics currently has a Zacks Rank #2 (Buy). In the past 60 days, estimates for BEAM’s 2025 loss per share have narrowed from $4.62 to $4.32.\nIn the past year, shares of Beam Therapeutics have risen 5.5% against the industry’s decline of 12.5%.\nImage Source: Zacks Investment Research\nSuccessful Development of Pipeline Candidates Holds the Key for BEAM\nLast month, the company announced new safety and efficacy data from the BEACON study evaluating BEAM-101 in SCD patients with severe vaso-occlusive crises.\nInitial data from the BEACON study supported the potential for meaningful clinical differentiation of BEAM-101 as compared to currently available treatments for SCD. The data showed that treatment with BEAM-101 led to a robust and durable increase in fetal hemoglobin of more than 60% and a reduction in sickle hemoglobin to less than 40%.\nTreatment with BEAM-101 also demonstrated rapid neutrophil and platelet engraftment and normalized or improved markers of hemolysis in the given patient population.\nBesides BEAM-101, BEAM is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for treating glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.\nPatient dosing in the phase I/II study evaluating BEAM-301 for treating GSD1a is expected to begin shortly.\nThe company is developing BEAM-302 in a phase I/II dose-escalation study for treating AATD. Initial data from multiple cohorts of the study are expected in the first half of 2025.\nEach of these programs is expected to have important catalysts during 2025.\nBeam Therapeutics ended 2024 on a high. Positive regulatory updates and the successful development of its hematology and liver genetic disease programs should help the stock gain further in 2025.\nOther Stocks to Consider\nSome other top-ranked stocks in the biotech sector are Voyager Therapeutics, Inc. VYGR, Harmony Biosciences Holdings, Inc. HRMY and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.58 for 2025. In the past year, shares of VYGR have plunged 27.3%.\nVYGR’s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%.\nIn the past 60 days, estimates for Harmony Biosciences’ earnings per share have increased from $2.64 to $3.22 for 2025. In the past year, shares of HRMY have rallied 22.5%.\nHRMY’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 147.24%.\nIn the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.70 for 2025. In the past year, shares of CSTL have surged 28.4%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBeam Therapeutics Inc. (BEAM) : Free Stock Analysis Report\nVoyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nHarmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2506893707"}